Role of Catechol-O-Methyltransferase (COMT)-Dependent Processes in Parkinson’s Disease and L-DOPA Treatment

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 3, 2012-05 ,pp. : 251-263

Bentham Science Publishers

Access to resources Recommend Favorite

L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 11, Iss. 4, 2011-12 ,pp. : 305-320

Bentham Science Publishers

Access to resources Recommend Favorite

Designing prodrugs for the treatment of Parkinson's disease

By Sozio Piera   Cerasa Laura Serafina   Abbadessa Anna   Di Stefano Antonio  

Expert Opinion on Drug Discovery, Vol. 7, Iss. 5, 2012-05 ,pp. : 385-406

Informa Healthcare

Access to resources Recommend Favorite

Elevated Homocysteine Levels in Parkinson's Disease: Is there Anything Besides L-Dopa Treatment?

By  

Current Medicinal Chemistry, Vol. 17, Iss. 3, 2010-01 ,pp. : 213-221

Bentham Science Publishers

Access to resources Recommend Favorite

Animal models of Parkinson’s disease and L-dopa induced dyskinesia: How close are we to the clinic?

By Lane Emma   Dunnett Stephen  

Psychopharmacology, Vol. 199, Iss. 3, 2008-08 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite